StockData
NeoGenomics Inc logo

NeoGenomics Inc (NEO) stock

NEONasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 11/3025% below fair value
$15.29+0.04 (+0.26%)

Close on Nov 18, 2026Market cap $1.98BP/E –Yield –

NeoGenomics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

NeoGenomics's revenue for the twelve months ending Sep 30, 2026 was $787.75M, up 11.1% year over year. For fiscal 2025 it was $727.33M, up 10.1% from the year before. Over ten years it grew 22.0% a year on average. The highest annual figure on record is $727.33M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$727.33M+10.1%
FY2024Dec 31, 2024$660.57M+11.6%
FY2023Dec 31, 2023$591.64M+16.1%
FY2022Dec 31, 2022$509.73M+5.2%
FY2021Dec 31, 2021$484.33M+9.0%
FY2020Dec 31, 2020$444.45M+8.7%
FY2019Dec 31, 2019$408.83M+47.7%
FY2018Dec 31, 2018$276.74M+15.2%
FY2017Dec 31, 2017$240.25M+3.6%
FY2016Dec 31, 2016$231.81M+132.3%
FY2015Dec 31, 2015$99.80M+14.6%
FY2014Dec 31, 2014$87.07M+31.0%
FY2013Dec 31, 2013$66.47M+11.0%
FY2012Dec 31, 2012$59.87M+37.7%
FY2011Dec 31, 2011$43.48M+26.5%
FY2010Dec 31, 2010$34.37M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$209.25M+11.4%
Q2 FY2026Jun 30, 2026$201.66M+11.2%
Q1 FY2026Mar 31, 2026$186.67M+11.1%
Q4 FY2025Dec 31, 2025$190.17M+10.6%
Q3 FY2025Sep 30, 2025$187.80M+11.9%
Q2 FY2025Jun 30, 2025$181.33M+10.2%
Q1 FY2025Mar 31, 2025$168.04M+7.5%
Q4 FY2024Dec 31, 2024$172.00M+10.6%
Q3 FY2024Sep 30, 2024$167.82M+10.4%
Q2 FY2024Jun 30, 2024$164.50M+12.0%
Q1 FY2024Mar 31, 2024$156.24M+13.9%
Q4 FY2023Dec 31, 2023$155.55M+12.1%
Q3 FY2023Sep 30, 2023$151.95M+18.0%
Q2 FY2023Jun 30, 2023$146.92M+17.5%
Q1 FY2023Mar 31, 2023$137.22M+17.1%
Q4 FY2022Dec 31, 2022$138.71M+10.3%
Q3 FY2022Sep 30, 2022$128.78M+6.1%
Q2 FY2022Jun 30, 2022$125.07M+2.8%
Q1 FY2022Mar 31, 2022$117.17M+1.4%
Q4 FY2021Dec 31, 2021$125.73M-0.2%
Q3 FY2021Sep 30, 2021$121.34M-3.3%
Q2 FY2021Jun 30, 2021$121.72M+39.9%
Q1 FY2021Mar 31, 2021$115.53M+9.0%
Q4 FY2020Dec 31, 2020$126.00M+17.9%
Q3 FY2020Sep 30, 2020$125.44M+19.8%
Q2 FY2020Jun 30, 2020$86.98M-14.5%
Q1 FY2020Mar 31, 2020$106.03M+10.9%
Q4 FY2019Dec 31, 2019$106.87M+39.7%
Q3 FY2019Sep 30, 2019$104.67M+51.5%
Q2 FY2019Jun 30, 2019$101.71M+50.1%
Q1 FY2019Mar 31, 2019$95.58M+50.7%
Q4 FY2018Dec 31, 2018$76.48M+24.5%
Q3 FY2018Sep 30, 2018$69.10M+16.8%
Q2 FY2018Jun 30, 2018$67.75M+8.8%
Q1 FY2018Mar 31, 2018$63.42M+10.4%
Q4 FY2017Dec 31, 2017$61.42M+1.5%
Q3 FY2017Sep 30, 2017$59.14M–
Q2 FY2017Jun 30, 2017$62.26M–
Q1 FY2017Mar 31, 2017$57.43M–
Q4 FY2016Dec 31, 2016$60.49M–

More NeoGenomics figures

See a number that looks wrong?